Biomind Labs Inc. (BMNDF)

USD 0.31

(0.0%)

Market Cap (In USD)

23.84 Million

Revenue (In USD)

-

Net Income (In USD)

-1.21 Million

Avg. Volume

253.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.0887-0.5739
PE
-
EPS
-
Beta Value
0.082
ISIN
CA0907021012
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Alejandro Antalich
Employee Count
-
Website
https://www.biomindlabs.com
Ipo Date
2021-07-27
Details
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammation, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.

More Stocks